^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    MRDVision

    Company:
    Inocras
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    1year
    Setting a New Standard in MRD Detection: Achieving Parts-per-Million Level Sensitivity with Inocras Whole Genome Platform and Ultima ppmSeqâ"¢ (AMP 2024)
    In addition to comprehensive cancer profiling, Inocras's MRDVision employs the WGS approach for ultra-sensitive, panel-free detection of minimal residual disease (MRD) at the parts-per-million (ppm) level. This workshop explores the clinical integration of Inocras' WGS technology for cancer profiling and MRD detection, demonstrating how our solutions provide actionable insights with broad clinical impact while achieving fast turnaround time and affordability.
    CancerVision • MRDVision
    1year
    Whole genome MRD detection with One-in-a-Million LOD: Inocras launches WGS-based, panel-free MRDVision, leveraging Ultima ppmSeqTM Technology (Businesswire)
    "Inocras...has introduced MRDVision, a minimal residual disease (MRD) detection solution showcasing a limit of detection (LOD) down to one-in-a-million. MRDVision combines Inocras’s WGS cancer profiling platform, CancerVision, and Ultima Genomics’ ppmSeq™ technology to deliver high-accuracy detection of circulating tumor DNA. This assay offers a low limit of detection, straightforward workflow, and fast turnaround time, all at a low cost."
    Launch
    |
    MRDVision